Hexarelin
Hexarelin Acetate • Also called Hexarelin Acetate
Hexarelin is a legacy growth-hormone secretagogue still searched in peptide and bodybuilding markets, but we do not currently have a clean FDA category or approved-drug pathway for it.
Current status
Restricted
Growth-hormone-related interest, with current federal compounding constraints still in play.
FDA category
No clear FDA signal
Can pharmacies compound this?
No
Reclassification expected?
Unclear
FDA has at least flagged distribution and listing problems around hexarelin APIs, but that is not the same as a clear approved pathway or 503A evaluation track.
Primary Use
Growth-hormone-related interest
Also searched as
Hexarelin Acetate
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Dec 8, 2025
Current status signal recorded: No clear FDA category or approved-drug pathway identified; FDA warning-letter posture shows listing and misbranding problems around distributed Hexarelin Acetate API..
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Get notified...
Get notified when Hexarelin status changes
State-specific notes
Texas
Secretagogues without a clear federal footing remain difficult for pharmacies to support.